Landscape Capital Management L.L.C. Invests $53,000 in Neuronetics, Inc. (NASDAQ:STIM)

Landscape Capital Management L.L.C. purchased a new position in Neuronetics, Inc. (NASDAQ:STIM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 69,263 shares of the company’s stock, valued at approximately $53,000.

Several other institutional investors and hedge funds also recently modified their holdings of STIM. GSA Capital Partners LLP boosted its stake in Neuronetics by 64.5% during the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock valued at $60,000 after buying an additional 30,837 shares in the last quarter. Gabelli Funds LLC boosted its stake in Neuronetics by 88.2% during the second quarter. Gabelli Funds LLC now owns 48,000 shares of the company’s stock valued at $86,000 after buying an additional 22,500 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in Neuronetics by 33.4% during the second quarter. First Eagle Investment Management LLC now owns 1,039,009 shares of the company’s stock valued at $1,870,000 after buying an additional 260,000 shares in the last quarter. First Washington CORP boosted its stake in Neuronetics by 88.8% during the second quarter. First Washington CORP now owns 1,274,540 shares of the company’s stock valued at $2,294,000 after buying an additional 599,455 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Neuronetics by 124.5% during the second quarter. Renaissance Technologies LLC now owns 322,200 shares of the company’s stock valued at $580,000 after buying an additional 178,700 shares in the last quarter. Institutional investors own 53.59% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. William Blair reaffirmed a “market perform” rating on shares of Neuronetics in a research note on Monday, August 12th. JMP Securities decreased their target price on Neuronetics from $7.00 to $3.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 14th. Finally, Canaccord Genuity Group decreased their target price on Neuronetics from $6.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th.

Neuronetics Trading Up 9.6 %

NASDAQ:STIM opened at $0.97 on Tuesday. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. Neuronetics, Inc. has a 1-year low of $0.52 and a 1-year high of $5.07. The firm has a market capitalization of $29.44 million, a price-to-earnings ratio of -0.79 and a beta of 2.21. The stock has a fifty day simple moving average of $0.90 and a 200 day simple moving average of $1.41.

Insider Activity at Neuronetics

In other Neuronetics news, Director Robert Cascella acquired 100,000 shares of Neuronetics stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average cost of $0.75 per share, with a total value of $75,000.00. Following the purchase, the director now owns 453,098 shares in the company, valued at approximately $339,823.50. The trade was a 28.32 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders purchased 137,776 shares of company stock worth $105,860 in the last quarter. 9.80% of the stock is owned by company insiders.

Neuronetics Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.